Similarly, CDK4/6i can resensitize therapy-resistant tumors to EGFR inhibitors, MET/TRK inhibitors, and MEK inhibitors by suppressing the growth of tumor cells in multiple pre-clinical models, in vitro and in vivo [194,195,196,197]. This evidence concerns the gene MAP2K7 and neoplasm.